Ингибитор ангиотензинпревращающего фермента или блокаторы рецепторов ангиотензина: с чего начать лечить гипертензию

1. FDA approves aliskiren: First new antihypertensive on the market in more than 10 years. http://www.theheart.org/article/774487.do
2. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13: 1100–8. [PMID: 11912272]
3. Mancia G, De Backer G, Dominiczak A et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
4. Dulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–6.
5. Messerli FH, Yuzefpolskaya M. Is an ACE inhibitor plus an ARB more effective than either drug alone? Cleve Clin J Med 2009; 76 (12): 693–6.
6. The ALLHAT study group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. JAMA 2002; 288: 2981–97.
7. Ausilia Maione, Sankar D. Navaneethan, Giusi Graziano et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26 (9): 2827–47. doi:10.1093/ndt/gfq792
8. Blood Pressure Lowering Treatment Trialists’ Collaboration. Bloodpressure dependent and independent effects of agents that inhibit therenin-angiotensin system. J Hypertens 2007; 25: 951–8.
9. Barnett AH, Bain SC, Bouter P et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952–61.
10. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension [Internet]. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN.Rockville (MD): Agency for Healthcare Research and Quality (US); 2007.
11. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012. DOI:10.1093/eurheartj/ehs075
12. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
13. Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE)—recent analyses. J Hypertens Suppl 2006; 24: S107–14.
14. NICE clinical guideline 127 Hypertension: clinical management of primary hypertension in adults www.nice.org.uk/guidance/CG127
15. Pfeffer MA, McMurray JJV, Velazquez EJ et al., for the valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
16. Dickstcin K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360 (9335): 752–60.
17. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the losartan heart failure survival study ELITE EE. Lancet 2000; 355: 1582–87.
18. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
19. ONTARGET: Telmisartan shows similar benefit to ramipril in high-risk vascular disease/diabetes patients http://www.theheart.org/article/852451.do
20. Father MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systemic overview of data from individual patients. ACEInhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575–81.
21. Национальные рекомендации по диагностике и лечению артериальной гипертонии (ВНОК, Российское медицинское общество по артериальной гипертонии). Кардиоваскулярная терапия и профилактика (Прил.). 2008; 7 (6).
22. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
23. Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BloodPressure. Hypertension 2003; 42: 1206–52.
24. Aronow WS, Fleg JL, Pepine CJ et al. «ACCF/AHA 2011 ExpertConsensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology FoundationTask Force on Expert Consensus Documents» as it appeared in the May 17, 2011, issue of the Journal. J Am Coll Cardiol 2011; 57: 2037–114.
25. Dahlof B, Gosse P, Gueret P et al. The PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressureand left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063–70.
26. Elliott W, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
27. Беленков Ю.Н., Мареев В.Ю. От имени рабочей группы исследования ЭПИГРАФ. Эналаприл плюс индапамид в лечении стабильной артериальной гипертонии: оценка эффективности и безопасности рациональной комбинированной фармакотерапии (Эпиграф). Первые результаты Российского многоцентрового исследования. Сердце. 2003; 2 (4): 159–64.
28. Беленков Ю.Н. и рабочая группа исследования ЭПИГРАФ-2. Эналаприл плюс индапамид в лечении АГ: оценка эффективности и безопасности рациональной фармакотерапии. Применение нефиксированной комбинации эналаприла и индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ 2. Сердце. 2005; 4 (5): 277–86.
29. Angiotensin-Converting Enzyme Inhibitor-Induced Cough: ACCP Evidence-Based Clinical Practice Guidelines Peter V. Dicpinigaitis. Chest 2006; 129; 169S–173S. DOI 10.1378/chest. 129.1_suppl.169S

Н.А.Ваулин 

Городская клиническая больница №29 им. Н.Э.Баумана, Москва